Comparison of plasma, whole blood and capillary blood concentrations of venlafaxine and desvenlafaxine

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00016339

Enrollment

Registered

2020-02-20

Start date

2018-11-13

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diseases, which are treated with venlafaxine

Interventions

Group 1: Patients who take venlafaxine will be asked to give written informed consent on an additional blood withdrawal (only one drop of blood) out of the fingertip with a microsampling device. The f

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: intake of venlafaxine

Exclusion criteria

Exclusion criteria: pregnancy

Design outcomes

Primary

Measure	Time frame
correlation between drug concentration in plasma, whole blood and capillary blood	—

Secondary

Measure	Time frame
Possibility to calculate the plasma concentration out of the capillary blood concentration	—

Countries

Germany

Contacts

Public ContactMike Stern

Pharmazeutische und Medizinische ChemieKlinische Pharmazie

mike.stern@uni-muenster.de0251 83 32171

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026